GRC 54276

Glenmark Specialty S.A. · Phase 1 active Small molecule

At a glance

Generic name	GRC 54276
Sponsor	Glenmark Specialty S.A.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRC 54276 CI brief — competitive landscape report
GRC 54276 updates RSS · CI watch RSS
Glenmark Specialty S.A. portfolio CI